Welcome to to the Irish Medical Times website
This site is aimed at healthcare professionals.
Are you a healthcare professional?
This site contains information, news and advice for healthcare professionals.
You have informed us that you are not a healthcare professional and therefore we are unable to provide you with access to this site.

September 3, 2015

Levocetirizine Teva

Company: Teva Pharmaceuticals Ireland.
Legal category: Prescription. GMS. Sport permitted.
Active ingredient: Levocetirizine diHCl 5mg.
Description: White to off white, film coated oval shaped tablet marked LC5 on one side.
Presentation: 28, €6.63.
Indications: Symptomatic treatment of perennial allergic rhinitis, seasonal allergic rhinitis and chronic idiopathic urticaria.
Pharmacology: Levocetirizine, the (R) enantiomer of cetirizine, is a potent and selective antagonist of peripheral H1-receptors. Binding studies revealed that levocetirizine has high affinity for human H1-receptors (Ki = 3.2 nmol/l). Pharmacodynamic studies in healthy volunteers demonstrate that, at half the dose, levocetirizine has comparable activity to cetirizine, both in the skin and in the nose.
Dosage: Adult: 5mg once daily. Treatment duration depends on the type, duration and course of the complaints; hay fever: 3-6 weeks, short-term pollen exposure: 1 week. May be used for up to 6 months. Renal impairment, see SPC. Elderly: As per adults. Children: Over 6 years, as per adults. Under 6 years, not recommended.
Contraindications: Hypersensitivity to levocetirizine, to other piperazine derivatives or to any of the excipients. Patients with severe renal impairment (creatinine clearance <10ml/min).
Special precautions: Pregnancy, lactation. Driving/using machines. Contains lactose.
Drug interactions: Caution: Alcohol or other CNS depressants.
Adverse drug reactions: Somnolence, headache, dry mouth, fatigue.
Full prescribing information and references available from Teva Pharmaceuticals Ireland. Telephone: 1800 201700.